Biomarkers to Predict Response to Multi-RTK Targeted Therapy in Advanced Colorectal Cancer
Abstract
Cetuximab is an antibody that targets the oncogene EGFR and is approved for use in advanced CRC. However, multiple resistancemechanisms to cetuximab exist that may be present at the outset or develop during treatment. We have shown a new mode of cetuximabresistance, due to increased phosphorylation of MET and RON RTKs. We also identified increased expression of the glutamate transporter,SLC1A7, in PDXs with high MET/RON phosphorylation. Here, we hypothesize that SLC1A7 contributes to the cetuximab resistance, and thatmodulation of glutamate levels may be a novel strategy to counter cetuximab resistance.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2022
- Accession Number
- AD1191282
Entities
People
- Bhuminder Singh
Organizations
- Vanderbilt University Medical Center